A randomised, double-blind, placebo-controlled, multicentre phase IV study to evaluate the efficacy and safety of dutasteride 0.5mg administered orally daily for 24 weeks to reduce the risk of acute urinary retention relapse following successful trial without catheter

Trial Profile

A randomised, double-blind, placebo-controlled, multicentre phase IV study to evaluate the efficacy and safety of dutasteride 0.5mg administered orally daily for 24 weeks to reduce the risk of acute urinary retention relapse following successful trial without catheter

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Urinary retention
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Nov 2007 Status change from recruiting to discontinued.
    • 14 Aug 2007 Status changed from initiated to recruiting.
    • 25 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top